Literature DB >> 9365200

Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?

R J Santen1, S J Santner, R J Pauley, L Tait, J Kaseta, L M Demers, C Hamilton, W Yue, J P Wang.   

Abstract

Studies of breast tumor homogenates from women with breast cancer have demonstrated the synthesis of estrogens in situ through the enzyme aromatase. The present series of investigations sought to determine which cell type within the tumor is responsible for local estrogen biosynthesis, and whether or not the amount produced is biologically important. Accordingly, we utilized an indirect immunohistochemical scoring method (H-score) to determine the relative amount of enzyme present in tumor epithelial and stromal cells. This revealed a value of 13 for tumor stromal cells and 4.8 for the epithelial component. Contributing to this difference is the fact that a greater percentage of cells in the tumor were stromal (45%) than epithelial (37%). To obtain direct evidence that tumor stromal cells could synthesize estrogens, we isolated and grew these cells in tissue culture. Stromal cells originating from within the tumor could be stimulated by known enhancers of transcription to produce nearly as much aromatase as is found in placental microsomes. Stromal cells isolated from benign tissue distal to the tumor exhibited properties similar to those of the tumor stroma. Epithelial cells, in contrast, did not respond to these enhancers and had low levels of aromatase basally. To obtain proof of the principle that local estrogen synthesis can be biologically meaningful, we measured tumor tissue estradiol levels and growth rates in aromatase-transfected MCF-7 cells implanted into nude mice. Local synthesis resulted in tumor levels ranging from 300 to 800 pg/g and growth rates substantially higher than in non-aromatase-containing tumors. These data suggest that tumor stromal cells contribute the major portion of estrogen synthesized in tumors, and that this local synthesis can increase tumor estradiol levels and growth rates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365200

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  14 in total

Review 1.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

2.  Lactogens and estrogens in breast cancer chemoresistance.

Authors:  Gila Idelman; Eric M Jacobson; Traci R Tuttle; Nira Ben-Jonathan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

3.  The functions of key residues in the inhibitor, substrate and cofactor sites of human 3beta-hydroxysteroid dehydrogenase type 1 are validated by mutagenesis.

Authors:  James L Thomas; Vance L Mack; Jingping Sun; J Ross Terrell; Kevin M Bucholtz
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-24       Impact factor: 4.292

Review 4.  Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.

Authors:  James L Thomas; Kevin M Bucholtz; Balint Kacsoh
Journal:  J Steroid Biochem Mol Biol       Date:  2010-08-22       Impact factor: 4.292

5.  Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue.

Authors:  Sarah A Andres; James L Wittliff
Journal:  Endocrine       Date:  2011-08-21       Impact factor: 3.633

6.  Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells.

Authors:  James L Thomas; Kevin M Bucholtz; Jingping Sun; Vance L Mack; Balint Kacsoh
Journal:  Mol Cell Endocrinol       Date:  2008-10-08       Impact factor: 4.102

Review 7.  Targeting the tumor microenvironment.

Authors:  Paraic A Kenny; Genee Y Lee; Mina J Bissell
Journal:  Front Biosci       Date:  2007-05-01

8.  Structure/function of the inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 and type 2 by trilostane.

Authors:  James L Thomas; Vance L Mack; Jason A Glow; Delaram Moshkelani; J Ross Terrell; Kevin M Bucholtz
Journal:  J Steroid Biochem Mol Biol       Date:  2008-05-03       Impact factor: 4.292

Review 9.  Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Authors:  Molly M Morgan; Brian P Johnson; Megan K Livingston; Linda A Schuler; Elaine T Alarid; Kyung E Sung; David J Beebe
Journal:  Pharmacol Ther       Date:  2016-05-21       Impact factor: 12.310

10.  HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis.

Authors:  Rajeshwar Rao Tekmal; Hareesh B Nair; Rao P Perla; Nameer Kirma
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.